OR-OREGON-SYMPHONY
9.2.2021 19:17:04 CET | Business Wire | Press release
The Oregon Symphony is proud to announce that acclaimed Austrian-born conductor David Danzmayr will serve as its next Music Director with the launch of its 2021-2022 season and the symphony’s 125th anniversary year. Regarded as one of today’s most gifted conductors, Danzmayr recently served as Chief Conductor of the Zagreb Philharmonic Orchestra and Music Director of ProMusica Chamber Orchestra. He has conducted orchestras at some of the world's most prominent concert halls in Germany, Italy, Scotland and major cities across the United States. Danzmayr follows esteemed Music Director Carlos Kalmar , who has held the position with the Oregon Symphony for the last 18 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005045/en/
“We are thrilled to have David joining the Oregon Symphony as a creative leader with a unique artistic vision,” shares Scott Showalter, Oregon Symphony President and CEO. “His inaugural season, with the implementation of his Creative Alliance, reflects his desire to embrace wide-ranging cultures while inspiring and challenging audiences, and is sure to open another rich chapter in Oregon Symphony history.”
Danzmayr holds a strong belief that a composer’s musical expression is shaped by their personal environment, family heritage and culture, which will be reflected in the Symphony’s 2021-2022 season programming and launch of the Oregon Symphony Creative Alliance. Danzmayr’s vision unites a wide-range of musical innovators to create vibrant work from unique perspectives. Under Danzmayr, the Creative Alliance will feature extraordinary artists and cultural thought leaders, including Nathalie Joachim, Gabriela Lena Frank, Jun Märkl, Gabriel Kahane, Simone Lamsma and Johannes Moser.
“The Oregon Symphony is one of the county's top orchestras, with talented musicians and a passionate community, and I am honored to have been selected as its next Music Director,” says Danzmayr.” As part of my agenda, I’m committed to building upon the Symphony's high standard of excellence with music that is meaningful to Oregon audiences.”
Danzmayr will join the four-time Grammy-nominated Oregon Symphony for its pivotal 125th anniversary, marking a profound milestone as the Symphony continues its legacy as the oldest orchestra in the Western United States.
"Oregon is proud to share 125 years with our beloved Oregon Symphony, and I want to personally welcome David Danzmayr as its new Music Director,” says Gov. Kate Brown. “The Oregon Symphony is one of our state’s artistic treasures, and the last 18 years with Carlos Kalmar as Music Director have been phenomenal. I can't wait to see what the symphony achieves under David’s leadership."
The Oregon Symphony will announce its 2021-2022 season in March 2021. For information about David Danzmayr, visit www.orsymphony.org/Danzmayr .
About Oregon Symphony
Led by Music Director Carlos Kalmar, the Oregon Symphony serves more than 235,000 people annually through concerts and award-winning education and community programs. The Symphony continues to innovate through series such as SoundSights, Sounds of Home and SoundStories. Follow the Oregon Symphony on Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom